Osteoplex
Natural health product licensed in Canada
- Licence holder
- Natural Equivalents Incorporated
- NPN or DIN-HM
- 80007592
- Status
- Inactive licence
- Licence date
- 11 September 2008
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
- Dose déclarée au-delà d'une limite
Calcium: up to 1,350 mg a day according to the dosing instructions published by Health Canada (9 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 800 mg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- Dose déclarée au-delà d'une limite
Phosphore: up to 675 mg a day according to the dosing instructions published by Health Canada (9 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 450 mg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Calcium Source : Phosphate de calcium, dibasique | 150 mg | 1,350,000 µg |
| Calcium Source : Carbonate de calcium | 150 mg | 1,350,000 µg |
| Vitamine K1 Source : Phytonadione | 12.5 mcg | 112.5 µg |
| Phosphore Source : Phosphate de calcium, dibasique | 75 mg | 675,000 µg |
Non-medicinal ingredients
Microcrystalline cellulose, Hypromellose, Stéarate de magnésium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | minimum: 2 Capsule ; maximum: 3 Capsule | 3 Tous les jours |
Uses authorised in Canada
Helps in the development and maintenance of bones. Helps in the absorption and use of calcium and phosphorus. Calcium intake, when combined with sufficient vitamin D, a healthy diet, and regular exercise, may reduce the risk of developing osteoporosis.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Consult a health care practitioner prior to use if you have a liver disorder. Consult a health care practitioner prior to use if you are taking blood thinners.
- Effets indésirables connus
Some people may experience diarrhea.
Source
Official Health Canada record, licence 80007592
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.